Kaviaar schreef op 17 februari 2022 08:49:
Hi ..,
Thank you for reaching out and for your candor.
Mr. Petti will be issuing a shareholder letter within the coming weeks to give further details on all progress in 2022, but right now all milestones that we've conveyed before are on track for this year for our CAR T candidates. That includes continuous enrollment and dosing in the KEYNOTE-B79 trial and IMMUNICY-1 trial for cohorts 4 and 5. Data is expected second half of 2022. These program updates will allow us to take data driven decisions on potential next steps for both programs, including potentially moving into Phase 2 development.
Also so you know, Filippo does not have another job and being CEO is his fulltime commitment and passion.
Would you like a call with the management team? We definetly try to be as transparent as we can so happy to get you in touch, or answer or any other questions you might have.
Thank you,
Sara
Sara Zelkovic
Communications & IR Director
m: +1 724 575 2922
szelkovic@celyad.com